Clinical efficacy of epirubicin combined with oxaliplatin transcatheter arterial chemoembolization in the treatment of patients with advanced primary liver cancer
Clinical efficacy of epirubicin combined with oxaliplatin transcatheter arterial chemoembolization in the treatment of patients with advanced primary liver cancer
Objective To investigate the clinical efficacy of epirubicin combined with oxaliplatin transcatheter arteri-al chemoembolization(TACE)in the treatment of patients with advanced primary liver cancer.Method A total of 96 pa-tients with advanced primary liver cancer were divided into control group(n=43)and observation group(n=53)according to different treatment methods.Patients in the control group received oxaliplatin TACE treatment,and patients in the ob-servation group received epirubicin combined with oxaliplatin TACE treatment.The clinical efficacy,tumor markers[vas-cular endothelial growth factor(VEGF),alpha fetoprotein(AFP)]levels,liver function indexes[alanine aminotransferase(ALT),albumin(ALB),total bilirubin(TBIL)]and the occurrence of adverse reactions were compared between the two groups.Result The total effective rate of observation group was higher than that of control group,and the difference was statistically significant(P＜0.05).After treatment,the VEGF and AFP levels in both groups were lower than those be-fore treatment,and the VEGF and AFP levels in observation group were lower than those in control group,and the differ-ences were statistically significant(P＜0.05).After treatment,the ALT and TBIL levels in both groups were lower than those before treatment,the ALB levels were higher than those before treatment,the ALT and TBIL levels in observation group were lower than those in control group,the ALB level was higher than that in control group,and the differences were statistically significant(P＜0.05).There was no significant difference in the total incidence of adverse reactions be-tween the two groups(P＞0.05).Conclusion Epirubicin combined with oxaliplatin TACE in the treatment of patients with advanced primary liver cancer can improve clinical efficacy,reduce the levels of tumor markers,and improve liver function without increasing adverse reactions.
维普
万方数据